"The voice for cancer physicians and their patients in Massachusetts."

FDA approval of TUKYSA® (tucatinib) tablets for oral use in combination with trastuzumab

20 Jan 2023 2:49 PM | Katy Monaco (Administrator)

FDA announce a new approval of TUKYSA® (tucatinib, Seagen Inc.) tablets, for oral use in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Access the Full Prescribing Information for TUKYSA. Read More.

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software